SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-18-010607
Filing Date
2018-08-09
Accepted
2018-08-09 17:13:58
Documents
61
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rasp-20180630.htm   iXBRL 10-Q 1012089
7 EXHIBIT 31.1 ex311_1.htm EX-31.1 16171
8 EXHIBIT 31.2 ex312_2.htm EX-31.2 11925
9 EXHIBIT 32.1 ex321_3.htm EX-32.1 4808
10 EXHIBIT 32.2 ex322_4.htm EX-32.2 4339
11 EXHIBIT 10.1 ex101_5.htm EX-10.1 151401
  Complete submission text file 0001213900-18-010607.txt   5687065

Data Files

Seq Description Document Type Size
2 DEFINITION rasp-20180630_def.xml EX-101.DEF 217456
3 PRESENTATION rasp-20180630_pre.xml EX-101.PRE 369559
4 CALCULATION rasp-20180630_cal.xml EX-101.CAL 36811
5 LABEL rasp-20180630_lab.xml EX-101.LAB 720754
6 SCHEMA rasp-20180630.xsd EX-101.SCH 44518
12 EXTRACTED XBRL INSTANCE DOCUMENT rasp-20180630_htm.xml XML 836042
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0929
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 181006319
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences